Building nanotools for enahnced therapeutic performance..............
About NBMI...................
Company Overview
NanoBioMagnetics (NBMI) is a nanobiomaterials company pioneering an emerging area of nanomedicine referred to as organ-assisting-device (OAD) technologies, which employ magnetically responsive nanoparticles (MNP), when under the incluence of external shaped magnetic fields, to cause or drive a desired physiological event. OAD healthcare applications are being developed under two proprietary platforms:
Biostable Implants: MNP, implanted in tissue, nanomechanically drive tissue movements or vibrations under the influence of an external oscillating magnetic field.
Site-Specific Drug Delivery: MNP-therapeutic constructs, under the influence of external shaped magnetic fields, concentrate at a target site, concurrent with tissue uptake.
As a nanobiomaterials company, NBMI has established collaborations with major research institutions for the validation of its OAD healthcare technologies. When successfully transferred to the clinical sector, OAD technologies will provide the physician and patient with new more effective therapeutic options for addressing the medical requirements of disease management.
NBMI's proprietary magnetic vectoring technology also creates a pipeline of OAD technology applications, also under some stage of collaborative development, that include:
William Yuill, Ph.D., Physical Chemistry, has served as Manager of Process Development for two major US corporations. He has industrial experience in heat transfer, fluid flow, process modeling and reactor design as well as expertise in aerosol processes. Dr. Yuill is listed as co-inventor or sole inventor on 12 US Patents. In the early 90’s, Dr. Yuill was the program leader for the process development of nanoparticle titanium dioxide, a broad spectrum UVA/UVB attenuator. Dr. Yuill provides the team with expertise in nanoparticle physics and nanofabrication methods based on aerosol processes.
Dr. Jim Klostergaard, Professor of Molecular and Cellular Oncology at The M D Anderson Cancer Center (MDACC), and Principal investigator on NBMI’s collaboration with MDACC studying the site-specific vectoring of chemotherapeutics. Dr. Klostergaard's research interests and activites include tumor necrosis factor, drug carriers, sphingolipids, drug copolymers. His work also includes paclitaxel copolymer formulations in Taxol-resistant human ovarian carcinoma nude mouse xenograft models that show improved survival and even achieved some cures in small animal models. His work with NBMI has focused on the magnetic vectoring of paclitaxel constructs in small animal breast and ovarian tumor models.
Charles Seeney, M.S. Polymer Science, is Founder and President of NanoBioMagnetics (NBMI), which is the fourth technology venture startup under his direction and leadership. He previously was Founder and President of NanoSource Technologies, Inc. (NSTI), whose IP was acquired by the DuPont Corp (2002). His industrial career spans 25+ years since receiving his degree from the University of Akron, OH. He began his career as a Research Scientist with Fortune 200 Companies, eventually becoming a Director of R&D. In the mid-80’s, his career interests turned to Technology Deployment when he started an internal venture, IMCERA Bioproducts, for a Fortune 200 Company which was eventually acquired by the Mallinckrodt Chemical SBU. Over his career, Seeney has been awarded 18 US Patents, with ten applications currently pending. He has also been published in peer reviewed journals.
Donald Gibson, M.S., Biochemistry, brings twenty plus years of academic and industrial research experience to NBMI and XetaComp. As Associate Director of Operations for a medical diagnostic venture, he was responsible for maintaining GMP protocols in the production of key materials for the diagnostic device. As Senior Scientist, Mr. Gibson will provide process development expertise in the design of specific nanoparticle configurations for the client. Mr. Gibson is published in several peer-reviewed journals and is an Adjunct Professor of Chemistry at the University of Central Oklahoma.
